Cargando…
The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib
PURPOSE: Patients with hepatocellular carcinoma (HCC) who might benefit most from anti-angiogenesis therapy remain unknown. In recent years, neutrophil-to-lymphocyte ratio (NLR), an indicator of inflammatory response, has received particular attention in HCC. Herein, we explored the prognostic value...
Autores principales: | Wang, Huaqi, Wang, Zhiwei, Hou, Zhenyu, Yang, Xuejiao, Zhu, Keyun, Cao, Manqing, Zhu, Xiaolin, Li, Huikai, Zhang, Ti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434860/ https://www.ncbi.nlm.nih.gov/pubmed/34522141 http://dx.doi.org/10.2147/CMAR.S311526 |
Ejemplares similares
-
Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial
por: Hou, Zhenyu, et al.
Publicado: (2020) -
Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma
por: Yang, XueJiao, et al.
Publicado: (2020) -
Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma
por: Gu, Xiaoying, et al.
Publicado: (2022) -
Resection of “down-staged” advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report
por: Hou, Zhenyu, et al.
Publicado: (2020) -
Role of Neutrophil-to-Lymphocyte Ratio (NLR) in Patients with Mycosis Fungoides
por: Di Raimondo, Cosimo, et al.
Publicado: (2023)